Total revenues increased to $874.8 million in 2025, up from $450.7 million in 2024, representing a $424.1 million increase. ORLADEYO revenue (excluding the European business) grew by $168.7 million, attributed to strong patient demand, price increases, and higher paid shipments. License revenue saw a substantial increase of $244.0 million, primarily from a $243.3 million license of intellectual property to Neopharmed Gentili. The company reported a net income of $263.9 million in 2025, a significant turnaround from a net loss of $88.9 million in 2024, marking its first annual GAAP profitability. Acquired Astria Therapeutics, Inc. on January 23, 2026, adding navenibart (Phase 3 for HAE) and STAR-0310 (Phase 1a for atopic dermatitis) to the product pipeline. Received FDA approval in December 2025 for an oral pellet formulation of ORLADEYO for prophylactic therapy in pediatric HAE patients aged 2 to <12 years. Successfully sold its European ORLADEYO business to Neopharmed Gentili for $250.0 million in cash proceeds, with potential for up to $14.0 million in future revenue milestones. Paid off the outstanding principal balance of $198.7 million on the Pharmakon Loan Agreement in October 2025, incurring a one-time loss on extinguishment of debt of $17.3 million. Entered into a new Loan Agreement with Blackstone on January 23, 2026, securing $400.0 million in initial term loans, with an option for an additional $150.0 million. Facing a patent infringement lawsuit from Annora Pharma Private Limited regarding four ORLADEYO patents expiring in 2039, following Annora's submission of an ANDA for a generic version.